anifrolumab (Saphnelo)

From Aaushi
Jump to navigation Jump to search

Indications

Adverse effects

* cytopenias & thrombotic events not observed

Mechanism of action

Notes

  • manufacturer AstraZeneca

More general terms

References

  1. Walsh N Thumbs Up From FDA for Anifrolumab in Lupus. Wonderful news for the lupus community, expert says. MedPage Today August 2, 2021 https://www.medpagetoday.com/rheumatology/lupus/93856
  2. Shaw K, Sanchez-Melendez S, Taylor D et al Assessment of Clinical Response to Anifrolumab in Patients With Refractory Discoid Lupus Erythematosus. JAMA Dermatol. Published online March 15, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36920401 https://jamanetwork.com/journals/jamadermatology/fullarticle/2802155